Exhibit 10.3

 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Change Order Form # 26

 

Change order under Agreement dated: Fifth Amendment to Development and Clinical
Supplies Agreement dated December 14, 2012

 

Between:  Radius Health, Inc and 3M

 

Project Name: For the development of Radius’ Abaloparatide compound delivered
via 3M’s Microstructured Transdermal Delivery System

 

Change requested by: Radius
Name: Michele Gehrt
Company: 3M

Date: 13May2015

 

Description of change:

 

Radius has requested that 3M continue to progress the redevelopment of the
Abaloparatide sMTS product to achieve a PK profile comparable to
Abaloparatide-SC, as evaluated in [*] . This change order will progress the work
completed in Change Order #22.

 

Scope:

 

3M to produce supplies of the sMTS Abaloparatide product ([*]) to achieve a PK
profile comparable to SC injection. Redevelopment to increase the amount of
Abaloparatide released may include changes in [*].  3M to prepare [*] product
configurations for evaluation in [*] studies.

 

Assumptions:

 

·                3M will progress several product configurations that will build
on the knowledge from previous w,ork.

·                3M will evaluate the [*] product configurations via [*].

·                The JTT will agree upon the product configurations to be taken
into each [*] study.

·                Supplies for [*] studies would be produced as for past
preclinical studies (non-GLP, non­ sterile) and shipped to the facility of
Radius’ designation.

·                 Stability for promising configurations would be characterized
only grossly

 

DELIVERABLES

 

·                Samples (approx [*] patch assemblies) for promising
configurations agreed to by the JTT for further evaluation by Radius in [*]. [*]
product configurations will be provided for [*] studies.

·                Gross stability evaluations for promising patch assembly
configurations (limited testing at up to [*] time points for [*] storage
condition).

 

1

--------------------------------------------------------------------------------

 

·                Analysis of residual content on dosed arrays will be conducted
if agreed to by JTT as necessary for understanding outcomes of the studies.

 

TIMING

 

The required effort in hours, duration of the study in months, and expected end
dates for the study covered by this work plan are summarized in the table below.

 

Task

 

Estimated
Effort
(hours)

 

Estimated
Duration
(months)

 

Estimated
Direct Costs
($)

 

Estimated End
Date*

 

Reformulation Tasks; Assessment of Release in [*]; Preparation of Samples for PK
Evaluation in [*]

 

300

 

1

 

$

2,500

 

31May2015

 

 

--------------------------------------------------------------------------------

*timing depends on duration and scheduling of [*] studies

 

Total Estimated Costs: $ 67,000

 

In all other respects, the terms and conditions of the Agreement remain in full
force and effect.

 

Requested task, dates and costs are approved by:

 

 

 

Company: Radius Health, Inc

Company: 3M

Name: Gary Hattersley

Name: Michele Gehrt

Signature:

/s/ Gary Hattersley

 

Signature:

/s/ Michele Gehrt

Position: CSO

Position: Commercialization Mgr

Date (dd/mm/yy): 13 May 2015

Date (dd/mm/yy): 13/05/15

 

2

--------------------------------------------------------------------------------